Floatz logo

Droxidopa

Progressive Supranuclear Palsy

Loma Linda UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Progressive Supranuclear Palsy cohort.

Asset / SponsorPhaseRating
IOFLUPANE
GE Healthcare
Phase 3BB
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
IOFLUPANE
GE Healthcare
Phase 3BB
Riluzole
King's College London
Phase 3B
[18F]MNI-958
Invicro
Phase 1B

View all 26 →

Same molecule, other indications

Droxidopa is also rated in:

primary orthostatic hypotensionDormant
BBB
Indicative ·
76 / 100
View asset →
Orthostatic HypotensionDormant
BBB
Indicative ·
74 / 100
View asset →
pure autonomic failureDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →